Abstract
TB-402, a human monoclonal antibody that partially inhibits Factor VIII activity (FVIII:C), is being developed as a long-acting antithrombotic agent. The primary goal of this study was to investigate the tolerability of TB-402 in healthy male volunteers. Secondary objectives were to determine the pharmacokinetics and pharmacodynamics of TB-402. In this ascending-dose study, healthy subjects aged 18 to 45 years were randomly assigned in a 2:1 ratio to receive TB-402 administered as a single intravenous bolus at 0.015, 0.1, 0.5, 2.5, 12.5, 37.5, 188, 620, or 1860 microg/kg or matching inactive vehicle (placebo). An older group (55-75 years) was also administered the highest dose that was well tolerated in the younger group (1860 microg/kg). Adverse events (AEs) were obtained from spontaneous reporting and from answers to nonleading questions asked by the principal investigator and study staff during follow-up visits on days 4, 7 (+/-1 day), 14 (+/-1 day), 21 (+/-2 days), 28 (+/-3 days), 42 (+/-3 days), and 56 (+/-3 days) after TB-402 administration. AEs were monitored up to the last study visit on day 56 after the administration of TB-402 or placebo, with special attention to bleeding events. The pharma-codynamic assessment of TB...Continue Reading
References
Apr 15, 1991·Annals of Internal Medicine·P K Jones, O D Ratnoff
Apr 1, 1970·The Journal of Clinical Investigation·A MorellT A Waldmann
Mar 19, 1999·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·E G BrownS Wood
Jan 13, 2000·Haemophilia : the Official Journal of the World Federation of Hemophilia·A J StewartC A Ludlam
Aug 19, 2000·The New England Journal of Medicine·P A KyrleS Eichinger
Dec 21, 2000·JAMA : the Journal of the American Medical Association
Aug 9, 2003·Lancet·A SrámekF R Rosendaal
Jan 14, 2004·Journal of Thrombosis and Haemostasis : JTH·M DewerchinM Jacquemin
Mar 23, 2006·Blood·Iris PlugFrits R Rosendaal
Feb 12, 2009·Journal of Thrombosis and Haemostasis : JTH·M JacqueminP Badenhorst
Nov 10, 2009·Current Opinion in Biotechnology·Patrick Y MullerFrank R Brennan
Citations
Jun 7, 2013·Thrombosis and Haemostasis·Maurits L van Montfoort, Joost C M Meijers
Jul 24, 2013·Expert Opinion on Investigational Drugs·Gentian Denas, Vittorio Pengo
Mar 1, 2011·Expert Opinion on Emerging Drugs·Gentian Denas, Vittorio Pengo
Feb 15, 2012·Chest·Jeffrey I WeitzMeyer Michel Samama
Apr 26, 2013·Thrombosis and Haemostasis·Peter VerhammeMarco Tangelder
May 17, 2013·Thrombosis and Haemostasis·Francesco Dentali, Nicoletta Riva
May 1, 2012·Journal of Thrombosis and Haemostasis : JTH·M TangelderP Verhamme
Feb 3, 2011·Journal of Thrombosis and Haemostasis : JTH·P VerhammeUNKNOWN TB-402 Study Group
Feb 27, 2013·British Journal of Clinical Pharmacology·Elizabeth TranterSteve Warrington
Jul 23, 2011·Thrombosis Research·J EmmerechtsP Verhamme
Nov 4, 2010·Therapeutic Advances in Cardiovascular Disease·Antonio Gómez-OutesEmilio Vargas-Castrillón
Sep 28, 2017·Expert Opinion on Drug Discovery·Antonio Gómez-OutesMª Luisa Suárez-Gea
Apr 4, 2017·Biomolecules & Therapeutics·Joo Hee KimHye Sun Gwak
Oct 26, 2018·Expert Opinion on Pharmacotherapy·Orsolya SzékelyGregory Yoke Hong Lip
Dec 12, 2017·Expert Opinion on Investigational Drugs·Gerasimos DimitropoulosGregory Y H Lip
Mar 7, 2020·Nature Reviews. Drug Discovery·Nigel MackmanJeffrey I Weitz
Oct 8, 2020·Expert Review of Clinical Pharmacology·Nan ZhaoYimin Cui